Research
Hormonal
Persistent hyperglycemia accelerates endogenous AGE formation through the Maillard reaction and dicarbonyl stress, leading to RAGE activation, oxidative stress, and insulin resistance.
Maintaining blood glucose levels within target ranges is critical to preventing the formation of endogenous AGEs and subsequent tissue damage.
StrongSupportsVERY_HIGH confidence
Uncontrolled hyperglycemia is considered to be the principal etiology of diabetic complications, as it leads to the production of AGEs [4,6]. ... The engagement of AGEs with its chief cellular receptor, RAGE, activates a myriad of signaling pathways such as MAPK/ERK, TGF-β, JNK, and NF-κB, leading to enhanced oxidative stress and inflammation.
Why this rating
Well-established pathophysiological mechanism supported by extensive literature cited in the review.
Source
Advanced Glycation End Products and Diabetes Mellitus: Mechanisms and Perspectives
Mariyam Khalid et al. · Biomolecules · 2022
DOI 10.3390/biom12040542
narrative_reviewCited 801×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Exogenous advanced glycation end products (AGEs) from heat-processed foods contribute significantly to systemic AGE accumulation, promoting oxidative stress, inflammation, and insulin resistance in type 2 diabetes.Good
- The AGEs/RAGE axis contributes to pancreatic beta cell toxicity and apoptosis via oxidative stress and islet amyloid polypeptide (IAPP) aggregation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →